查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867192

DNA修復藥物市場按藥物類別、作用機制、適應症、給藥途徑和最終用戶分類－2025-2032年全球預測

DNA Repair Drugs Market by Drug Class, Mechanism Of Action, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，DNA 修復藥物市場將成長至 163.1 億美元，複合年成長率為 7.44%。

關鍵市場統計數據
基準年 2024 91.8億美元
預計年份：2025年 98.7億美元
預測年份 2032 163.1億美元
複合年成長率 (%) 7.44%

全面概述定義現代腫瘤學中DNA修復療法的科學進展、法規環境和商業性需求。

DNA修復療法領域融合了分子生物學、精準腫瘤學和新型藥物療法，正在重新定義多種腫瘤的治療方法。近年來，隨著對腫瘤基因組學和合成致死機制理解的不斷深入，靶向DNA損害反應路徑的治療方法已從學術研究轉變為特定適應症的臨床常用療法。該領域目前涵蓋了已開發的藥物類別以及旨在利用癌細胞新發現的弱點的新興抑制劑。

基因組精準醫療、適應性檢測和聯合療法如何重塑DNA修復治療領域的研發重點和商業模式

DNA修復療法生態系統正在經歷一場變革，而這場變革正在改變研發重點、臨床試驗設計和商業模式。基因組分析和生物標記檢驗的進步迫使研發人員設計具有分子選擇性和適應性的試驗，從而能夠快速識別有效患者，同時減少無效患者的暴露。同時，將DNA修復抑制劑與免疫療法、標靶治療或傳統細胞毒性藥物合併使用的策略，已從探索性方案發展為系統性的開發路徑，這反映出策略性重心正向多模態療法轉變。

2025年關稅趨勢將如何影響全球藥品供應鏈、研發時間表以及DNA修復療法的獲取策略

政策變化，包括已宣布或將於2025年實施的關稅，使跨境醫藥原料和成品供應鏈再次受到關注。由於許多DNA修復療法依賴特殊的活性藥物原料藥、複雜的化學合成以及進口的實驗室耗材，關稅帶來的成本壓力可能會影響生產經濟效益和臨床供應物流。為此，各公司正在重新評估供應商多樣性，盡可能將關鍵生產環節遷回國內，並協商長期採購協議以降低價格波動。

細緻入微的細分市場挑戰表明，藥物類別、作用機制、適應症、給藥途徑和最終用戶趨勢如何共同塑造了不同的研發和商業化策略。

細分市場層面的洞察揭示了不同作用機制、適應症、給藥途徑和最終用戶群所對應的獨特研發路徑和商業性考量，這些因素共同決定了投資重點。按藥物類別分類，競爭格局和臨床環境涵蓋了ATM抑制劑、Atr抑制劑、 DNA甲基轉移酵素抑制劑、HDAC抑制劑和PARP抑制劑。在這些類別中， DNA甲基轉移酵素抑制劑又可分為已上市藥物和在研藥物，而PARP抑制劑則呈現出多層次的市場結構，包括品牌藥、非專利和在研藥物，這影響著定價和市場定位策略。這種多樣性要求在藥物生命週期的各個階段採取差異化策略：已上市學名藥需要擴大市場准入範圍並採取以銷量為導向的策略。

基於區域監管、報銷和基礎設施實際情況的策略差異化將決定臨床開發重點和市場進入策略。

區域趨勢對DNA修復療法研發、監管溝通和商業化方面的策略決策具有重要意義。在美洲，人們尤其重視那些強調快速監管溝通、支付方證據產生和生物標記主導適應症的推廣路徑。臨床試驗網路和腫瘤聯盟為後期評估和真實世界證據的收集提供了強大的支持。歐洲、中東和非洲（EMEA）地區的市場環境則更為複雜，監管協調、報銷差異和醫療基礎設施的不同要求企業制定個人化的上市計劃和差異化的定價策略。製造商通常會根據衛生技術評估（HTA）框架和集中式/分散式報銷機制，優先選擇該地區的國家進行早期上市。

領先開發商採取的企業策略包括：建立夥伴關係以加速產品推廣、整合診斷功能、建立穩健的供應鏈以及基於證據的商業化。

DNA修復療法領域的主要企業展現出通用的策略行為：建立合作夥伴關係以拓展聯合治療，投資伴隨診斷研發以支持精準的患者篩選，以及進行有針對性的併購和許可活動以強化互補資產。大型製藥企業正在擴大與生物技術公司的合作，以加速轉化科學發展並獲取新型化學類型和專有生物標記平台。同時，靈活的生物技術公司正利用早期概念驗證數據來協商共同開發契約並資金籌措臨床實驗試驗，從而建立一個以互補能力和風險共用為核心的生態系統，推動發展。

明確且可操作的經營團隊重點，以整合生物標記主導的證據、穩健的業務營運以及DNA修復項目的有針對性的商業化。

產業領導者應優先考慮一系列切實可行的舉措，將科學潛力轉化為持續的商業性成功。首先，將生物標記策略和衛生經濟學納入早期研發計劃，確保臨床試驗結果符合支付方預期和臨床決策。這將有助於申辦方縮短產品上市時間，並提升產品上市時的價值定位。其次，尋求策略聯盟，將互補的作用機製或治療方式結合，以增強聯合治療的實證基礎，並分散整個研發組合的風險。

一項結合專家訪談、全面二手資料和三角驗證分析技術的穩健的多方法研究設計，確保了研究的有效性和透明度。

為確保洞察的廣度和深度，本研究採用結構化的多方法整合數據，結合了第一手資料和第二手資料。第一手資料包括對腫瘤領域關鍵高管、大型和小型生物製藥公司高管、監管專家和市場進入負責人的訪談，以深入了解臨床開發、監管預期和商業化挑戰。第二手資料涵蓋同行評審文獻、臨床試驗註冊資訊、監管文件、專利概況和公司披露資訊，以驗證研究結果並檢驗戰略趨勢。

總之，我們強調，必須將基於機制的創新、證據生成和營運韌性結合起來，才能實現持續的臨床和商業性影響。

總之，DNA修復療法在腫瘤學領域中佔據著至關重要且快速發展的細分市場，科學進步、臨床檢驗和商業性可行性必須協同作用，才能真正造福患者。該領域的未來不僅取決於機制創新，還取決於整合生物標記、建立穩健的供應和生產策略以及產生實現廣泛應用所需的衛生經濟學證據的組織能力。策略夥伴關係和適應性試驗設計將迅速將有前景的機制轉化為永續的臨床應用方案，而在地化的上市計劃將決定患者接受治療的速度和範圍。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新興的PARP抑制劑聯合治療有望克服BRCA突變癌症的抗藥性
  • 基於 CRISPR 的標靶 DNA 修復治療方法在罕見遺傳疾病治療中的進展
  • 開發針對DNA損害反應激酶ATM和ATR的小分子抑制劑
  • 擴大精準腫瘤學研發管線，聚焦合成致死策略
  • 將基於生物標記的患者選擇納入DNA修復調節劑的臨床試驗
  • 人工智慧驅動的新型DNA修復候選藥物篩檢平台投資趨勢

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. DNA修復藥物市場依藥物類別分類

  • ATM抑制劑
  • ATR抑制劑
  • DNA甲基轉移酵素酶抑制劑
    • 已發布
    • 管道
  • HDAC抑制劑
  • PARP抑制劑
    • 品牌產品
    • 學名藥
    • 管道

9. DNA修復藥物市場依作用機轉分類

  • 單株抗體
  • 胜肽
  • 低分子化合物
    • ATM抑制劑
    • ATR抑制劑
    • DNA甲基轉移酵素酶抑制劑
    • HDAC抑制劑
    • PARP抑制劑

第10章 DNA修復藥物市場依適應症分類

  • 乳癌
    • HER2陽性
    • 荷爾蒙受體陽性
    • 三重否定
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第11章 DNA修復藥物市場依給藥途徑分類

  • 靜脈注射
  • 口服
  • 皮下注射

第12章 DNA修復藥物市場（依最終用戶分類）

  • 醫院
  • 藥局
  • 專科診所

第13章 DNA修復藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 DNA修復藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國DNA修復藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Clovis Oncology, Inc.
    • Pfizer Inc.
Product Code: MRR-99555D550531

The DNA Repair Drugs Market is projected to grow by USD 16.31 billion at a CAGR of 7.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.18 billion
Estimated Year [2025] USD 9.87 billion
Forecast Year [2032] USD 16.31 billion
CAGR (%) 7.44%

Comprehensive orientation to the scientific advancements, regulatory context, and commercial imperatives defining DNA repair therapeutics in contemporary oncology

The DNA repair therapeutics landscape represents a convergence of molecular biology, precision oncology, and novel drug modalities that together are redefining treatment approaches for multiple tumor types. In recent years, therapies targeting DNA damage response pathways have moved from academic curiosity to clinical staples in certain indications, driven by a deeper mechanistic understanding of tumor genomics and synthetic lethality. The field now spans established classes of agents alongside emergent inhibitors that seek to exploit newly discovered vulnerabilities in cancer cells.

This introduction synthesizes the state of play for stakeholders who require a concise, authoritative orientation. It outlines the technological drivers, regulatory context, and commercial considerations shaping development priorities. By placing clinical innovation in the context of operational realities-supply chain resilience, payer engagement, and biomarker deployment-this section equips decision-makers with the baseline perspective needed to interpret subsequent, more granular analyses. Transitioning from scientific promise to routine clinical integration remains the central theme, highlighting the interplay among translational research, regulatory pathways, and commercial strategy.

How genomic precision, adaptive trials, and combination strategies are collectively reshaping development priorities and commercial models across DNA repair therapeutics

The DNA repair therapeutics ecosystem is experiencing transformative shifts that are altering R&D priorities, clinical trial design, and commercial models. Advances in genomic profiling and biomarker validation have compelled developers to design trials that are both molecularly selective and adaptive, enabling faster identification of responders while reducing exposure for non-responders. Concurrently, combination strategies that pair DNA repair inhibitors with immunotherapies, targeted agents, or conventional cytotoxics have matured from exploratory regimens into structured development paths, reflecting a strategic recalibration toward multi-modal approaches.

On the technological front, the rise of next-generation sequencing and liquid biopsy platforms has increased the feasibility of real-time patient selection and monitoring, thereby tightening the feedback loop between clinical outcomes and molecular hypotheses. From a commercial standpoint, payers and health systems are increasingly demanding demonstrable value through biomarker-defined benefit, driving sponsors to integrate health economics and outcomes research earlier in development. As a result of these intersecting forces, the landscape is evolving from single-agent, indication-focused pursuits to more nuanced, mechanism-driven portfolios that emphasize precision, combination potential, and sustainable access models.

Implications of 2025 tariff dynamics on global pharmaceutical supply chains, development timelines, and access strategies for DNA repair therapeutics

Policy shifts involving tariff measures announced or implemented in 2025 have generated renewed attention to cross-border supply chains for pharmaceutical ingredients and finished products. For DNA repair therapeutics-many of which rely on specialized active pharmaceutical ingredients, complex chemical synthesis, and imported laboratory consumables-tariff-driven cost pressures can affect manufacturing economics and the logistics of clinical supply. In response, companies are reassessing supplier diversity, onshoring critical production steps where feasible, and negotiating longer-term procurement contracts to mitigate price volatility.

Beyond immediate cost implications, tariffs interact with regulatory and commercial levers. Higher input costs can prompt adjustments to portfolio prioritization, delaying lower-priority indications or pipeline candidates that require extensive global distribution channels. In parallel, procurement and tender practices among hospitals and health systems may shift toward domestic suppliers or incumbent therapies with established supply resilience, potentially complicating market access for newer entrants dependent on international manufacturing footprints. To navigate this environment, organizations are increasing visibility into tiered supplier risk, enhancing inventory forecasting for pivotal trials, and accelerating localization strategies for manufacturing and quality control infrastructure to sustain development timelines and patient access.

Nuanced segment-driven imperatives showing how drug class, mechanism, indication, route, and end-user dynamics combine to shape distinct development and commercialization strategies

Segment-level insights reveal distinct development pathways and commercial considerations across mechanisms, indications, routes, and end users that collectively define investment priorities. By drug class, the competitive and clinical landscape spans Atm inhibitors, Atr inhibitors, Dna methyltransferase inhibitors, Hdac inhibitors, and Parp inhibitors; within these groups, Dna methyltransferase inhibitors are bifurcated between launched agents and those in the pipeline, while Parp inhibitors present a layered market of branded, generic, and pipeline entrants that influence pricing and positioning strategies. This heterogeneity necessitates differentiated lifecycle approaches: launched agents require label expansion and real-world evidence generation, pipeline candidates demand translational validation and strategic partnerships, and generics call for access and volume-driven tactics.

Considering mechanism of action, therapies based on monoclonal antibodies, peptides, and small molecules exhibit divergent development and commercialization profiles, with small molecules further subdivided into Atm, Atr, Dna methyltransferase, Hdac, and Parp inhibitor chemotypes. The modality influences dosing paradigms, manufacturing complexity, and intellectual property strategies. Indication-focused segmentation highlights breast, ovarian, pancreatic, and prostate cancers as primary therapeutic arenas, with breast cancer further resolved into Her2 positive, hormone receptor positive, and triple-negative subtypes; such granularity drives unique biomarker needs and payer narratives for each subgroup. Route of administration-intravenous, oral, and subcutaneous-affects patient adherence, clinic resource utilization, and homecare opportunities, while end user segmentation across hospitals, pharmacies, and specialty clinics shapes distribution strategies and commercial engagement models. Taken together, these intersecting segments prescribe distinct development roadmaps, go-to-market architectures, and evidence-generation priorities that innovators must reconcile when allocating finite resources.

Regional strategic differentiation across regulatory, reimbursement, and infrastructure realities that determine clinical development priorities and market access approaches

Regional dynamics materially influence strategic decision-making across development, regulatory engagement, and commercialization for DNA repair therapeutics. In the Americas, there is a pronounced emphasis on rapid regulatory engagement, payer evidence generation, and adoption pathways that favor biomarker-driven indications; clinical trial networks and oncology consortia provide a robust environment for late-stage evaluation and real-world evidence capture. Europe, Middle East & Africa present a more heterogeneous landscape where regulatory harmonization, reimbursement diversity, and variable healthcare infrastructure necessitate tailored market entry plans and differentiated pricing strategies. Manufacturers often prioritize countries within the region for early launches based on HTA frameworks and centralized or decentralized reimbursement mechanisms.

Asia-Pacific demonstrates a mix of rapid innovation adoption in select markets and infrastructure-driven constraints in others. Several countries in Asia-Pacific prioritize domestic manufacturing and local clinical data, prompting sponsors to adapt trial designs and commercial models to meet local requirements. Cross-region considerations-such as regional clinical trial enrollment strategies, supply chain routing, and localized evidence generation-play a pivotal role in shaping program timelines and access. Ultimately, regional strategies must balance the imperative for global coordination with the need to localize regulatory, clinical, and commercial approaches to achieve sustainable patient access.

Corporate strategies observed among leading developers focusing on partnerships, diagnostics integration, resilient supply chains, and evidence-driven commercialization to accelerate adoption

Leading companies in the DNA repair therapeutics domain are demonstrating a common set of strategic behaviors: forging collaborative partnerships to expand combination regimens, investing in companion diagnostic development to support precise patient selection, and deploying targeted M&A or licensing activity to shore up complementary assets. Large pharmaceutical firms are increasingly partnering with biotechs to accelerate translational science and to gain access to novel chemotypes or unique biomarker platforms. At the same time, nimble biotechnology companies are leveraging early proof-of-concept data to negotiate co-development deals or to secure capital for pivotal trials, demonstrating an ecosystem where complementary capabilities and shared risk are central to progress.

Commercially, companies are aligning external affairs, medical affairs, and market access functions earlier in development to ensure that evidence generation addresses payer needs. Supply chain resilience and localized manufacturing are emerging as strategic priorities for firms seeking to protect launch timelines against geopolitical and tariff-related headwinds. Finally, the competitive landscape is prompting companies to differentiate through real-world evidence initiatives, patient support programs, and direct engagement with specialist centers to accelerate adoption where clinical benefit is clearest. These tactics collectively reflect a shift toward more integrated, evidence-driven commercialization strategies across incumbent and emerging players alike.

Clear, implementable priorities for leadership to align biomarker-driven evidence, resilient operations, and targeted commercialization for DNA repair programs

Industry leaders should prioritize a set of actionable initiatives that translate scientific promise into durable commercial success. First, integrate biomarker strategies and health economics into early development plans so that trials generate outcomes aligned with payer expectations and clinical decision-making. By doing so, sponsors can reduce time-to-access hurdles and improve value positioning at launch. Second, pursue strategic collaborations that pair complementary mechanisms or modalities to strengthen rationale for combination regimens and to diversify risk across development portfolios.

Third, build supply chain resilience by diversifying API sources, investing in regional manufacturing capacity where justified, and establishing robust inventory planning for pivotal trials. These actions mitigate exposure to tariff shocks and logistical disruptions. Fourth, invest in companion diagnostic partnerships and real-world evidence capture to substantiate effectiveness and to support label expansion efforts. Lastly, tailor regional go-to-market approaches that account for local regulatory, reimbursement, and infrastructure nuances, and deploy targeted stakeholder engagement to accelerate guideline adoption and clinician uptake. Executing these initiatives in a coordinated fashion will improve the likelihood that promising therapeutics transition to widely accessible standards of care.

Robust multi-method research design combining expert primary interviews, comprehensive secondary sources, and triangulated analytical techniques to ensure validity and transparency

This research synthesizes data from a structured multi-method approach combining primary and secondary sources to ensure breadth and depth of insight. Primary research included interviews with key opinion leaders in oncology, executives from small and large biopharmaceutical companies, regulatory specialists, and market access professionals to capture nuanced perspectives on clinical development, regulatory expectations, and commercialization challenges. Secondary research encompassed peer-reviewed literature, clinical trial registries, regulatory filings, patent landscapes, and company disclosures to triangulate findings and validate strategic trends.

Analytical techniques applied include pipeline mapping, competitive landscaping, and scenario-based impact assessment to understand how policy, clinical, and commercial variables interact. Quality controls included source triangulation, expert validation workshops, and a documented audit trail for critical assumptions. The methodology acknowledges limitations related to evolving clinical data and policy changes, and it therefore highlights where findings are most sensitive to new trial outcomes or regulatory developments. Where possible, the analysis emphasizes reproducible methods and transparent rationale so that stakeholders can adapt the approach to their specific decision-making needs.

Concluding synthesis emphasizing the imperative to align mechanistic innovation, evidence generation, and operational resilience to achieve durable clinical and commercial impact

In conclusion, DNA repair therapeutics occupy a pivotal and rapidly evolving niche within oncology where scientific advances, clinical validation, and commercial execution must align to realize patient benefit. The sector's future will be defined not only by mechanistic innovation but also by the ability of organizations to integrate biomarkers, build resilient supply and manufacturing strategies, and generate the health-economic evidence required for broad access. Strategic partnerships and adaptive trial designs will accelerate the translation of promising mechanisms into durable clinical options, while regionally tailored launch plans will determine the speed and extent of patient uptake.

Ultimately, success in this space demands coordinated action across R&D, regulatory affairs, supply chain, and commercial functions. Stakeholders who proactively address evidence generation, payer alignment, and operational resilience will be best positioned to transform scientific opportunity into sustainable therapeutic impact for patients across the major oncology indications served by DNA repair strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of PARP inhibitor combinations to overcome resistance in BRCA-mutated cancers
  • 5.2. Advances in CRISPR-based targeted DNA repair therapeutics for rare genetic disorders
  • 5.3. Development of small molecule inhibitors targeting DNA damage response kinases ATM and ATR
  • 5.4. Growth of precision oncology pipelines focusing on synthetic lethality strategies
  • 5.5. Integration of biomarker-driven patient selection in clinical trials for DNA repair modulators
  • 5.6. Investment trends in AI-driven screening platforms for novel DNA repair drug candidates

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Repair Drugs Market, by Drug Class

  • 8.1. Atm Inhibitors
  • 8.2. Atr Inhibitors
  • 8.3. Dna Methyltransferase Inhibitors
    • 8.3.1. Launched
    • 8.3.2. Pipeline
  • 8.4. Hdac Inhibitors
  • 8.5. Parp Inhibitors
    • 8.5.1. Branded
    • 8.5.2. Generic
    • 8.5.3. Pipeline

9. DNA Repair Drugs Market, by Mechanism Of Action

  • 9.1. Monoclonal Antibodies
  • 9.2. Peptides
  • 9.3. Small Molecules
    • 9.3.1. Atm Inhibitors
    • 9.3.2. Atr Inhibitors
    • 9.3.3. Dna Methyltransferase Inhibitors
    • 9.3.4. Hdac Inhibitors
    • 9.3.5. Parp Inhibitors

10. DNA Repair Drugs Market, by Indication

  • 10.1. Breast Cancer
    • 10.1.1. Her2 Positive
    • 10.1.2. Hormone Receptor Positive
    • 10.1.3. Triple Negative
  • 10.2. Ovarian Cancer
  • 10.3. Pancreatic Cancer
  • 10.4. Prostate Cancer

11. DNA Repair Drugs Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. DNA Repair Drugs Market, by End User

  • 12.1. Hospitals
  • 12.2. Pharmacies
  • 12.3. Specialty Clinics

13. DNA Repair Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. DNA Repair Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. DNA Repair Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AstraZeneca PLC
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Clovis Oncology, Inc.
    • 16.3.5. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DNA REPAIR DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DNA REPAIR DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DNA REPAIR DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DNA REPAIR DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY LAUNCHED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PIPELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATM INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ATR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DNA REPAIR DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE DNA REPAIR DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY PARP INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST DNA REPAIR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST DNA RE